The SOLOIST-WHF trial, which enrolled patients with diabetes and recent worsening heart failure, noted that sotagliflozin (SGLT1 and 2 inhibitors) therapy significantly lowered total number of deaths from cardiovascular causes and decreased the number of hospitalizations and urgent visits for heart failure compared with placebo when the medication was initiated before or shortly after discharge [55]. This evidence concerns the gene SLC5A1 and heart failure.